✦ LIBER ✦
Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
✍ Scribed by Zwierzina, H; Suciu, S; Loeffler-Ragg, J; Neuwirtova, R; Fenaux, P; Beksac, M; Harousseau, J; Nuessler, V; Cermak, J; Solbu, G
- Book ID
- 110056454
- Publisher
- Nature Publishing Group
- Year
- 2005
- Tongue
- English
- Weight
- 116 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0887-6924
No coin nor oath required. For personal study only.